Acadian Asset Management
LABP

Acadian Asset Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Acadian Asset Management’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-134
Closed -$2K – 1953
2024
Q1 		$2K Hold
134
– – ﹤0.01% 1539
2023
Q4 		$0 Hold
134
– – ﹤0.01% 1881
2023
Q3 		$0 Hold
134
– – ﹤0.01% 1923
2023
Q2 		$0 Hold
134
– – ﹤0.01% 1967
2023
Q1 		$0 Hold
134
– – ﹤0.01% 2044
2022
Q4 		$0 Hold
134
– – ﹤0.01% 1958
2022
Q3 		$0 Hold
134
– – ﹤0.01% 1909
2022
Q2 		$1K Hold
134
– – ﹤0.01% 1661
2022
Q1 		$1K Sell
134
-693
-84% -$17.6K ﹤0.01% 1618
2021
Q4 		$39K Buy
+827
New +$86.9K ﹤0.01% 1525

Acadian Asset Management's LABP Position: Q2 2024 in Review

Acadian Asset Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 134 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in LABP in Q4 2021 and held it in 10 quarters. The position peaked at $39K in Q4 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

  • Acadian Asset Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 134 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $2K.
  • Acadian Asset Management first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
  • Acadian Asset Management's Landos Biopharma, Inc. Common Stock position peaked at $39K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.